Peptide conjugation techniques are advancing CNS delivery of oligonucleotides, addressing blood-brain barrier challenges and improving therapeutic outcomes.
Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Voluntary exercise reshapes gut microbiota and tryptophan metabolism, with consequences for the hippocampus, the ...
Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.
The Fc fusion protein market thrives on innovative therapies targeting oncological and genetic disorders. Key opportunities lie in developing stable and soluble treatments, partnering with research ...
The Citizens Life Sciences Conference 2026 March 11, 2026 2:15 PM EDTCompany ParticipantsDave Gancarz - Chief Business ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...
Researchers at the University of California San Diego have uncovered how a single protein triggers two opposite responses in blood vessels—one inflammatory and one protective. This protein, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results